CUE vs HAL · rev $9.3M vs P/E 9.3, $19.05B cap
Cue Biopharma (CUE) versus Halliburton Company (HAL) — a side-by-side from cached financials, not a winner call.
Cue Biopharma (CUE) is a biotechnology company listed on US.
Halliburton Company (HAL) is a oil & gas equipment & services company listed on US.
Latest reported CUE revenue for 2024-12-31 was $9.3M. Net income was -$40.7M. Revenue was up 69.2% from 2023-12-31 to 2024-12-31. CUE currently screens at market cap $59.5M.
HAL does not have a complete income-statement cache yet.
CUE currently screens at market cap $59.5M. HAL currently screens at market cap $19.05B and trailing P/E 9.3.
Not investment advice. Open the CUE and HAL stock pages for the full models.
Not investment advice.